Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Estela Pineda,Marta Domenech,Ainhoa Hernández,Silvia Comas,Carmen Balaña
DOI: https://doi.org/10.2147/OTT.S366371
IF: 4
2023-01-25
OncoTargets and Therapy
Abstract:Estela Pineda, 1 Marta Domenech, 2 Ainhoa Hernández, 2 Silvia Comas, 3 Carmen Balaña 2 1 Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain; 2 Medical Oncology, Institut Catala d'Oncologia (ICO) Badalona, Barcelona, Spain; 3 Radiation Oncology, Institut Catala d'Oncologia (ICO) Badalona, Badalona, Spain Correspondence: Carmen Balaña, Institut Catala d'Oncologia (ICO) Badalona, Carretera Canyet s/n, Badalona, 08916, Spain, Tel +34 497 89 25, Fax +34 497 89 50, Email Virtually all glioblastomas treated in the first-line setting will recur in a short period of time, and the search for alternative effective treatments has so far been unsuccessful. Various obstacles remain unresolved, and no effective salvage therapy for recurrent glioblastoma can be envisaged in the short term. One of the main impediments to progress is the low incidence of the disease itself in comparison with other pathologies, which will be made even lower by the recent WHO classification of gliomas, which includes molecular alterations. This new classification helps refine patient prognosis but does not clarify the most appropriate treatment. Other impediments are related to clinical trials: glioblastoma patients are often excluded from trials due to their advanced age and limiting neurological symptoms; there is also the question of how best to measure treatment efficacy, which conditions the design of trials and can affect the acceptance of results by oncologists and medicine agencies. Other obstacles are related to the drugs themselves: most treatments cannot cross the blood-brain-barrier or the brain-to-tumor barrier to reach therapeutic drug levels in the tumor without producing toxicity; the drugs under study may have adverse metabolic interactions with those required for symptom control; identifying the target of the drug can be a complex issue. Additionally, the optimal method of treatment – local vs systemic therapy, the choice of chemotherapy, irradiation, targeted therapy, immunotherapy, or a combination thereof – is not yet clear in glioblastoma in comparison with other cancers. Finally, in addition to curing or stabilizing the disease, glioblastoma therapy should aim at maintaining the neurological status of the patients to enable them to return to their previous lifestyle. Here we review currently available treatments, obstacles in the search for new treatments, and novel lines of research that show promise for the future. Keywords: glioblastoma, research, challenges, endpoints, recurrent, treatment The incidence of malignant tumors of the central nervous system (CNS) is 7.08 per 100,000 inhabitants in the USA. Glioblastoma (GB) accounts for 47.7% of all CNS malignant tumors in adults, and patients have a median overall survival (OS) of only eight months and a 5-year survival of 5.8% (95% CI 5.5–6.1). 1 The incidence of GB is low compared to that of other tumors, but there is no localized and surgically curable form of GB as there is in other cancers, so all cases are considered grade 4. The standard first-line treatment for GB was established in 2005 as maximal safe surgery followed by radiotherapy plus concomitant and adjuvant temozolomide. 2 In the USA, tumor-treating fields can also be administered after chemoradiotherapy. This system delivers low-intensity, intermediate-frequency alternating fields via transducer arrays when applied to the scalp, exerting an antimitotic effect. 3 Unfortunately, only around 44–50% of patients are able to receive the full standard treatment, 4,5 only one fourth of those who start treatment are able to complete the six cycles of adjuvant temozolomide, 5 and only 60% of these patients receive second-line treatments. Fewer than 43% of GB patients are fit enough to be included in clinical trials. 6 The symptoms of GB and the sequelae of treatments often lead to functional dependence and cognitive impairment, 7 making it impossible for patients to return to their normal pre-diagnosis activities and impacting negatively on family life. There is thus great concern about patient quality of life during the extra period of survival conferred by treatment, especially on the maintenance of neurocognition and the adjustment of palliative and supporting treatments, including rehabilitation. 8,9 To date, the search for alternative effective treatments for GB has been unsuccessful. Here we review the standard of care and available therapies, obstacles in the search for new treatments, and new lines of treatment under investigation. Several treatments have shown some efficacy in specific patients at recurrence, including second surgery (S-S), re-irradiation, and re-treatment with temozolomide, nitrosoureas or bevacizumab (Figur -Abstract Truncated-
oncology,biotechnology & applied microbiology